U.S. markets closed

Immutep Limited (IMMP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.5200+0.3200 (+10.00%)
At close: 4:00PM EDT

3.5200 0.00 (0.00%)
After hours: 7:53PM EDT

Sign in to post a message.
  • P
    From the operation update "AIPAC reaches ~72% of events and TACTI-002 recruitment is progressing well". That means, and I hate to be blunt like this, 28% of participants are still living, which IMO will be a significant increase in OS. You can infer that from the data. The drug works, even in these last attempts for individuals who are out of choices.
  • b
    May 7 (Reuters) - Immutep Ltd (IMM) :

  • P
    If analysts out there have any deductive reasoning, I cannot fathom how this, for our dear Immutep, could not be colossal, immense, prodigious, pythonic, seminal... etcetera, etcetera and so forth:

    you got to cut and paste the link for some reason yahoo keeps removing it.
  • P
    I stand corrected. They are presenting results. We should know shortly:

    Poster Session
    Head and Neck Cancer
    Available starting on: Jun 4th 20219:00 AM EDT
    Head and Neck Cancer
    View all 74 Presentations
    1 Related presentation

    Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in...
    Irene Brana, Martin Forster, Antonio Lopez-Pousa, Bernard Doger, Patricia Roxburgh, Pawan Bajaj, Daniela Urueta Portillo, Vanesa Quiroga, Matthew Krebs, Christian Mueller, Frederic Triebel
  • P
    "Immutep (IMM.AX) is one of the most promising drug developers listed on
    the ASX. A core competency is its unsurpassed understanding of the
    biology of the lymphocyte activation gene-3 (LAG-3) and the development of
    therapeutics based on that knowledge. In this report, we take a deep-dive
    into Immutep’s project pipeline. We look at major factors in oncology drug
    development and the broader market and how Immutep are likely to support
    the value of its lead asset, eftilagimod alpha (efti), currently in mid-late-stage
    clinical trials. Finally, we look at the company’s intellectual property and
    management, the latter being often overlooked by investors."
  • b
    Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting

  • P
    Immutep files a 6-K with the SEC, This is required something when an event is going to happen to influence your stock. GSK filed a 6-K before the shingles vac was approved by the FDA. Its the foreign version of the 8-K to let the SEC know of something with significance.
    Form 6-K (report of foreign issuer [rules 13a-16 and 15d-16]) filed with the SEC
    Form 6-K (report of foreign issuer [rules 13a-16 and 15d-16]) filed with the SEC
  • P
    From what I can tell immutep is only participating in ASCO this year and not presenting. The ASCO dates are below, so we will know for sure by April 28, as that is when the abstract titles are released. They are however definitely presenting at Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit. Frédéric Triebel, CSO & CMO is scheduled to present Results of a Phase II Study in NSCLC. He will speak Thursday July 15th at 9:10 EDT. But there are no dates provided for abstract pre-release. So we may have to wait until the presentation date.
    His talk:
    A Soluble LAG-3 Protein (Eftilagimod Alpha) With An Anti-PD-1
    Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC
    • An MHC class II agonist (eftilagimod) used as an antigen presenting cell (APC) activator combined with an immune checkpoint inhibitor (ICI): a unique combination in immuno-oncology
    • Results in first and second (in PD-X refractory patients) lines non-small cell lung carcinoma (NSCLC)

    ASCO dates in case they do present:

    FEBRUARY 17, 2021 at 11:59 PM ET
    Abstract Submission Deadline
    MARCH 18, 2021
    Late-breaking Submission Deadline (Abstract placeholder is required by February 17 deadline)
    APRIL 1, 2021
    Abstract Notifications sent to First Author
    APRIL 11, 2021
    Abstract Withdrawal Deadline
    APRIL 28, 2021
    Abstract Titles Released
    APRIL 28, 2021
    Early Registration Deadline
    MAY 14, 2021
    Exhibits, Industry Expert Theater, Pharmaceutical Pipeline Directory, and Clinical Trials Directory Opens
    MAY 19, 2021 at 5:00 PM ET
    Proceedings I and Publish Only Abstracts Released on ASCO.org
    JUNE 3, 2021 at 5:00 PM ET
    Late-Breaking Abstracts (LBAs) Released on ASCO.org
    JUNE 4-8, 2021
    ASCO Annual Meeting
  • b
    Yes big news coming.
    It's just nobody seem to care about....
  • T
    In the 1990s Jim Allison, Ph. D. found that T cells are controlled by a safety mechanism or “brakes” – a negative immune checkpoint protein, CTLA-4. Allison got the Nobel prize. At the same time Frederic Triebel discovered the LAG gene or the "gas pedal"
    CEO Marc said check point inhibitor therapy has been stalled for 6 years. Studies to see if there is synergy between checkpoint inhibitors and LAG3 take time. Now multiple studies with BMS, Merck, Novartis will be coming out showing that targeting checkpoint inhibitors and LAG3 is give better results than either alone. And the FDA announced is going to help IMMP with Fast Tracking. How often do you see that with a small biotech? Not a bad week.
  • P
    Watch May 19TH.
    Abstracts will be available from 5pm US Eastern Time on 19 May 2021.
  • T
    take a look at last year's chart in front of the ASCO meeting there were a couple of huge spikes and news this year is a lot better
  • M
    Quarterly update this morning looks fantastic, we should finish the year very strong
  • P
    An excellent read. This year again laid out with all its potential... https://www.asx.com.au/asxpdf/20210414/pdf/44vjfp8306tb2t.pdf
  • I
    Immunotrader 10
    Sls will be launching on the 2 trial readouts this Quarter- $immp up 190% on weaker data UPDATE: Immutep shares soar 190% on positive results in trial of breast cancer treatment
    By Ciara Linnane
    Published: Dec. 10, 2020, 12:51 p.m. EDT
    Shares of Immumetp Ltd. (IMMP) an Australian biotech with a Nasdaq listing, soared 190% Thursday, after the company reported positive results from a trial of a treatment for metastatic breast cancer. The company said overall survival data from a Phase 2b study evaluating its lead product candidate eftilagimod alpha in combination with chemotherapy performed well compared with placebo and chemotherapy. The overall trend in OS in total population was a median survival benefit of plus 2.7 months. However, in patients under 65 years of age, the benefit was 7.1 months. The data were presented at the San Antonio Breast Cancer Symposium which is taking place this week. "Although the progression free survival data in the efti group did not show a significant improvement versus the comparator arm in AIPAC earlier this year, the OS data in general looks already very interesting and will mature further," AIPAC Principal Investigator, Hans Wildiers of University Hospital Leuven in Belgium said in a statement. "The OS data in subgroups such as those below age 65 years are highly encouraging and may lead to more effective treatment options for metastatic breast cancer patients." Maxim analyst Jason McCarthy raised his stock price target to $8 from $4 on the news. "The data around overall survival, particularly in pre-defined subgroups, suggests efti is having a meaningful and significant impact," McCarthy wrote in a note to clients. Maxim rates the stock a buy. Shares of Greenwich LifeSciences Inc. (GLSI) were up 45%, after gaining more than 2,000% on Wednesday, also on promising news for a breast cancer treatment. Immutep shares have gained 218% in the year to date, while the SPDR S&P Biotech ETF (XBI) has gained 48% and the S&P 500 (^GSPC) has gained 14%.
  • P
    GSK stopped their trials with feladilimab, which targets ICOS. https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-feladilimab-an-investigational-inducible-t-cell-co-stimulatory-icos-agonist/

    Probably won't impact IMMP price, but narrows the playing filed in Head and neck cancer and Non-small cell lung cancer. As much as I want any help for anyone suffering, this will put more eyes on LAG-3 in immuno oncology IMO.
    GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist
    GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist
  • Y
    Yahoo reader
    Great week, we are finally getting noticed.
    Huge cancer treatment potential, and some of the best partners in big pharma.
    Exciting, best of luck to all.